Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.2
Journals
JPM
Special Issues
Current Trends of Precision Medicine in Oncology
share announcement

Current Trends of Precision Medicine in Oncology

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Precision Oncology".

Deadline for manuscript submissions: 30 November 2026 | Viewed by 1022

Special Issue Editors

Dr. Ekene E. Nweke

E-Mail Website
Guest Editor
Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2017, South Africa
Interests: cancer biology; molecular biology; pancreatic cancer; gallbladder cancer; molecular pathways; cancer precision medicine; hepatopancreatobiliary diseases
Dr. Sylvester Omoruyi

E-Mail Website
Guest Editor
Faculty of Health Sciences, University of the Witwatersrand, Parktown, Johannesburg 2017, South Africa
Interests: brain tumors; neurodegenerative diseases; neuroprotective agents; drug discovery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer is a highly heterogeneous disease, making detection and treatment complex. As such, a one-size-fits-all approach to diagnosis and treatment is insufficient to provide effective and equitable care. Precision oncology, involving the integration of molecular, clinical, and imaging data, seeks to tailor cancer diagnosis, management, and treatment to the unique biological and clinical characteristics of each patient, thereby improving diagnostic and therapeutic efficacy. The Special Issue aims to provide a comprehensive overview of how precision medicine is transforming cancer research and care. We invite high-quality reviews and original research articles (including basic, clinical, and translational studies) highlighting current trends utilizing a multimodal and multidisciplinary approach to precision oncology. Topics of interest include, but are not limited to:

  • Pre-clinical and clinical studies evaluating multi-omics approaches (genomics, epigenomics, transcriptomics, proteomics, metabolomics, spatial and single-cell analyses) for cancer diagnosis, prognosis, risk stratification, and therapeutic decision-making.
  • Advances in biomarker discovery and validation.
  • Novel liquid biopsy technologies aimed at improving diagnosis and prognosis of cancer.
  • Computational and AI-driven analytics for identification of novel targets.
  • Targeted novel drug discovery for cancer therapy.
  • Integrative imaging modalities to improve cancer screening and detection.

Dr. Ekene E. Nweke
Dr. Sylvester Omoruyi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • precision oncology
  • multi-omics
  • biomarkers
  • liquid biopsy
  • cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

31 pages, 1319 KB  
Review
Molecular Oncodiagnostics in Precision Oncology: Integrating Tumor Transcriptomics, Patient Pharmacogenetics, and Ex Vivo Chemoresistance Testing to Improve Individual Chemotherapy Response
by Dario Rusciano
J. Pers. Med. 2026, 16(4), 176; https://doi.org/10.3390/jpm16040176 - 24 Mar 2026
Viewed by 792
Abstract
Background: Precision oncology has traditionally relied on genomic biomarkers to guide therapy selection; however, static molecular profiling often fails to predict real-world responses to cytotoxic chemotherapy. Increasing evidence suggests that treatment outcomes are determined by the interaction between tumor-intrinsic biology and host-specific [...] Read more.
Background: Precision oncology has traditionally relied on genomic biomarkers to guide therapy selection; however, static molecular profiling often fails to predict real-world responses to cytotoxic chemotherapy. Increasing evidence suggests that treatment outcomes are determined by the interaction between tumor-intrinsic biology and host-specific pharmacology. Functional ex vivo platforms, including patient-derived organoids and tumor slice cultures, provide a complementary phenotypic readout of drug sensitivity that reflects tumor architecture and microenvironmental interactions. Methods: This narrative review integrates recent experimental, translational, and clinical evidence on molecular oncodiagnostics combining tumor transcriptomics, germline pharmacogenetics, and ex vivo drug sensitivity testing. Relevant literature was identified through targeted searches of major biomedical databases, focusing on studies describing multi-omic predictive models, functional precision oncology platforms, and patient-derived tumor models. Results: Converging data indicate that integrated oncodiagnostic strategies can improve prediction of chemotherapy response beyond genomics-only approaches. Transcriptomic profiling captures dynamic pathway activity and resistance programs, pharmacogenetic testing informs host-specific toxicity and dosing constraints, and ex vivo assays enable direct phenotypic validation of drug efficacy. Together, these complementary approaches provide a biologically grounded framework for individualized therapy selection. Conclusions: The convergence of molecular profiling and functional phenotyping represents an emerging paradigm in precision oncology. Integrating multi-omic and functional data may enhance treatment prediction and reduce ineffective therapy, although prospective validation and standardization remain necessary for routine clinical implementation. Full article
(This article belongs to the Special Issue Current Trends of Precision Medicine in Oncology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop